Neurocrine Biosciences
NBIX
#1590
Rank
NZ$22.14 B
Marketcap
NZ$220.67
Share price
-0.77%
Change (1 day)
16.46%
Change (1 year)
Neurocrine Biosciences is an American biopharmaceutical company that develops treatments for neurological and endocrine-related diseases and disorders.

EPS for Neurocrine Biosciences (NBIX)

EPS in 2025 (TTM): NZ$7.40

According to Neurocrine Biosciences 's latest financial reports the company's current EPS (TTM) is NZ$7.33. In 2024 the company made an earnings per share (EPS) of NZ$5.75 an increase over its 2023 EPS that were of NZ$4.32.

EPS history for Neurocrine Biosciences from 2012 to 2025

Annual EPS

Year EPS Change
2025 (TTM)NZ$7.4028.63%
2024NZ$5.7533.07%
2023NZ$4.3257.76%
2022NZ$2.7469.47%
2021NZ$1.62-78.21%
2020NZ$7.42990%
2019NZ$0.6881.82%
2018NZ$0.37-113.5%
2017NZ-$2.770.62%
2016NZ-$2.7657.28%
2015NZ-$1.7525.61%
2014NZ-$1.4018.84%
2013NZ-$1.17-1085.71%
2012NZ$0.12

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Pfizer
PFE
NZ$2.31-68.45%๐Ÿ‡บ๐Ÿ‡ธ USA
AbbVie
ABBV
NZ$4.07-44.51%๐Ÿ‡บ๐Ÿ‡ธ USA
Eli Lilly
LLY
NZ$39.17 434.10%๐Ÿ‡บ๐Ÿ‡ธ USA
Repligen
RGEN
NZ$0.05104-99.30%๐Ÿ‡บ๐Ÿ‡ธ USA
Athersys
ATHX
NZ-$3.45-147.10%๐Ÿ‡บ๐Ÿ‡ธ USA
ANI Pharmaceuticals
ANIP
NZ$2.91-60.32%๐Ÿ‡บ๐Ÿ‡ธ USA
Palatin Technologies
PTN
NZ-$50.87-793.74%๐Ÿ‡บ๐Ÿ‡ธ USA
Royalty Pharma
RPRX
NZ$3.01-59.02%๐Ÿ‡ฌ๐Ÿ‡ง UK